Archive for the ‘Harvard spinoffs’ Category

Genocea Biosciences (Berkeley, Harvard) Closes $35 Million Series B Financing (01/03/2011)

April 11, 2011

Genocea Biosciences develops vaccines based on a platform that reduces the time to discover vaccine candidates. Among the company’s co-founders are Darren Higgins, Ph.D. Professor of Microbiology and Molecular Genetics and David Sinclair, Ph.D., Professor of Pathology, both at Harvard Medical School. The company was founded based on developments at both Berkeley and Harvard.

From the company’s press release:
Genocea Biosciences Inc., a vaccine discovery and development company pioneering a new class of T cell-based vaccines, today announced that it has closed a $35 million Series B round of venture financing, with new investors Johnson & Johnson Development Corporation (JJDC), Skyline Ventures and MP Healthcare Venture Management, Inc. (MPH) joining existing investors Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures. Stephen J. Hoffman, M.D., Ph.D., managing director at Skyline Ventures, joins the Genocea board in connection with the financing. In addition, Genocea also announced the appointment of industry veteran Seth Hetherington, M.D., to chief medical officer. read full press release

RainDance Technologies (Harvard) Continues Aggressive Expansion Across European Region (12/7/2010)

December 13, 2010

RainDance Technologies creates instruments for genomic selection. The company was founded by scientists from Harvard University, The Medical Research Centre in Cambridge, England, and the ESPCI in Paris. Co-founders from Harvard include Physics and Applied Physics Professor Dr. David Weitz and Postdoctoral Scientist Dr. Darren Link, who serves as the company’s Vice President, Research and Development.

From the company’s press release:
RainDance Technologies, Inc., a private company pioneering microdroplet-based technologies for single molecule and single cell analysis, today announced the latest addition to its worldwide commercial leadership team with the appointment of Mark Dronsfield, Ph.D., as Director of Sales for Europe. Dr. Dronsfield joins a growing commercial team of industry veterans that includes Richard H. Lussier, Vice President of Worldwide Sales and Ingrid Choupin, Managing Director of European Sales and Marketing. read full press release

RainDance’s (Harvard) Microdroplet Technology Recognized as a Breakthrough Invention (12/1/2010)

December 13, 2010

RainDance Technologies creates instruments for genomic selection. The company was founded by scientists from Harvard University, The Medical Research Centre in Cambridge, England, and the ESPCI in Paris. Co-founders from Harvard include Physics and Applied Physics Professor Dr. David Weitz and Postdoctoral Scientist Dr. Darren Link, who serves as the company’s Vice President, Research and Development.

From the company’s press release:
RainDance Technologies, Inc., a private company pioneering microdroplet-based technologies for single molecule and single cell analysis, today announced that the company has been recognized by the Museum of Science, Boston and the Boston Patent Law Association for its innovations and contributions to advancing the field of genetic research. read full press release

Joule Unlimited (Harvard, MIT) Expands Senior Management Team (11/29/2010)

December 13, 2010

Joule Unlimited, Inc. develops a platform for renewable fuel production. Among the co-founders are George Church, PhD, who is Professor of Genetics at Harvard Medical School, and and Noubar Afeyan, PhD, who is Lecturer at the MIT Sloan School of Management.

From the company’s press release:
Joule Unlimited, Inc. pioneer of Liquid Fuel from the Sun™, today announced the expansion of its senior management team to support the company’s rapid progress towards high-volume commercial production of renewable diesel fuel. Eric d’Esparbes has joined as Chief Financial Officer, and Kevin Madden has joined as Vice President of Biology Operations. read full press release

Cerulean Pharma Inc. (Harvard, MIT) Presents Clinical and Pre-Clinical Nanopharmaceutical Data at EORTC-NCI-AACR (11/18/2010)

December 12, 2010

Cerulean Pharma Inc., is a biopharmaceutical company focused on the development of nanotechnology-based therapeutics. The company was co-founded by MIT Professor of Health Sciences & Technology and Biological Engineering Ram Sasisekahran and Harvard Medical School Assistant Professor Shiladitya Sengupta.

From the company’s press release:
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company’s senior executives presented at the 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics,” ongoing in Berlin, Germany. read full press release

Cerulean Pharma Inc. (Harvard, MIT) Closes $24 Million in Series C Financing (11/15/2010)

November 16, 2010

Cerulean Pharma is a biopharmaceutical company focused on the development of nanotechnology-based therapeutics. The company was co-founded by MIT Professor of Health Sciences & Technology and Biological Engineering Ram Sasisekahran and Harvard Medical School Assistant Professor Shiladitya Sengupta.

From the company’s press release:
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company has closed a $24 million Series C financing led by Lilly Ventures, with participation from all other existing investors including Polaris Venture Partners, Venrock, Lux Capital, and Bessemer Venture Partners. In conjunction with the closing of the financing, Steve Hall, Ph.D., a Venture Partner at Lilly Ventures, has joined Cerulean’s board of directors. read full press release

Cerulean Pharma Inc. (Harvard, MIT) to Present at BIO-Europe and EORTC-NCI-AACR (11/11/2010)

November 13, 2010

Cerulean is a biopharmaceutical company focused on the development of nanotechnology-based therapeutics. The company was co-founded by MIT Professor of Health Sciences & Technology and Biological Engineering Ram Sasisekahran and Harvard Medical School Assistant Professor Shiladitya Sengupta.

From the company’s press release:
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company’s senior executives will be presenting at two major European conferences to be held in Munich and Berlin, Germany. read full press release

RainDance Technologies (Harvard) CEO Recognized For Leadership and Community Service (10/8/2010)

October 11, 2010

RainDance Technologies is a Harvard University spinoff that creates instruments for genomic selection.

Roopom Banerjee, President and CEO of RainDance Technologies, Inc., a private company pioneering microdroplet-based technologies for single-molecule and single-cell analysis, has been named by the Boston Business Journal to its 2010 “40 Under 40” list of local leaders. [read more]

RainDance Technologies (Harvard) to Present at Upcoming Investor Conferences (9/10/2010)

September 14, 2010

RainDance Technologies is a Harvard University spinoff that creates instruments for genomic selection.

RainDance Technologies, Inc., a private company pioneering microdroplet-based technologies for single-molecule and single-cell analysis, today announced that it will present at two upcoming investor conferences in September: the Stifel Nicolaus Healthcare Conference and the UBS Global Life Sciences Conference. [read more]